Medical Author: William C. Shiel Jr., MD, FACP, FACR
Medical Editor: Leslie J. Schoenfield, MD, PhD
A new drug is available for adult patients with moderate to severe rheumatoid arthritis who have not responded to other disease modifying antirheumatic drugs (DMARDs)! The brand name of the new drug is Kineret and its generic name is anakinra.
This is big news in the treatment of rheumatoid arthritis. You see, anakinra (Kineret) is a new type of biological response modifier (BRM) for treating this disease. Thus, anakinra (Kineret) acts by blocking the biological effects of the chemical messenger, Interleukin-1 (IL-1). IL-1 is a protein that is produced by many cells in the body. It is found, however, in increased amounts within joints that are inflamed by rheumatoid arthritis. In fact, IL-1 promotes the inflammation and destruction of cartilage and bone in rheumatoid arthritis. Accordingly, this BRM, like the traditional DMARDS, can prevent progressive joint destruction.
What are advantages of Kineret?
- Anakinra (Kineret) may be used alone or in combination with methotrexate (Rheumatrex) or other DMARDs.
- To date, no cases of the activation of tuberculosis or other opportunistic infections (such as serious fungus infections) have been reported with the use of anakinra (Kineret). In contrast, opportunistic infections have been reported with another type of BRM drugs that includes infliximab (Remicade) and etanercept (Enbrel). (These biological response modifiers work by blocking another of the body's promoters of joint inflammation called tumor necrosis factor, TNF).
- Patients can become intimately involved in their own treatment by self-injecting anakinra (Kineret) under the skin.
- Patients will have the option of self-injecting 100 mg prefilled syringes or loading these into a specially designed injector device, called the Simpleject™.
What are disadvantages of Kineret?
Dr. Shiel's perspective
Anakinra (Kineret) is an effective and relatively safe drug that has been studied in thousands of rheumatoid arthritis patients to date. While no data exists that directly compares anakinra (Kineret) with other agents in treating rheumatoid arthritis, it appears that the effectiveness rates of this drug in studies to date are comparable to existing DMARDs and biologic drugs. Furthermore, the Simpleject™ system of administration is relatively easy to use, even for patients with significant hand deformity.
So, which rheumatoid arthritis patients should receive this drug? First of all, I will offer anakinra (Kineret) to patients who have not responded to other disease modifying antirheumatic drugs (DMARDs). Thus, I will consider anakinra (Kineret) for patients who have not responded to traditional DMARDs, or do not want to use intravenous treatment with infliximab (Remicade), or cannot get etanercept (Enbrel) because of lack of insurance coverage. I will certainly also consider anakinra (Kineret) for patients with moderate to severe rheumatoid arthritis who have failed infliximab (Remicade) or etanercept (Enbrel).
Anakinra (Kineret) might be considered in patients with rheumatoid arthritis who have experienced a serious reaction (side effect) to another BRM agent (infliximab/Remicade or etanercept/Enbrel). Also, be aware that aggravation of congestive heart failure has been reported to be associated with infliximab usage. Therefore, anakinra (Kineret) may be an option for rheumatoid arthritis patients who have known significant heart disease. Finally, I personally will not prescribe anakinra (Kineret) together with the TNF-blocking drugs until more information is available to verify the safety of this combination.
It is noteworthy that at our recent national meeting of arthritis expe
For more information, please read the Kineret drug monograph.
Quick GuideRheumatoid Arthritis (RA) Symptoms & Treatment
Daily Health News
Rheumatoid Arthritis Resources
Subscribe to MedicineNet's Arthritis Newsletter